Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis
Summary:
The NIA seeks co-development partners and/or licensees for the further development of Cα-peptide as a therapeutic that inhibits islet amyloidosis.
Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics
Summary:
NICHD is seeking research co-development partners and/or licensees for development of this invention as a male contraceptive.
Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines
Description of Technology:
Ovarian cancer is one of the most common and lethal types of gynecological malignancies worldwide, accounting for approximately 295,000 new cases and 185,000 deaths annually. The high lethality rate is due to multiple reasons, including recurrence and the resistance of recurrent tumors to chemotherapy. Cell line models are crucial for preclinical cancer studies, to identify mechanisms of disease, to study drug resistance, and to screen for candidate therapeutics.
EGFRvIII Antibodies for the Treatment of Human Cancer
Summary:
The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.
Description of Technology:
Epidermal growth factor receptor variant III (EGFRvIII) is a variant of EGFR that is an excellent target for immunotherapy because of its expression in cancer cells and not in normal cells.
Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members
Summary:
The National Eye Institute (NEI) seeks research collaborations and/or licensees for the use of iPS cells.
Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers
Description of Technology:
Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children and makes up 3% of all childhood cancers. Aveloar Rhabdomyosarcoma is the most aggressive subtype and is primarily established through a chromosomal translocation resulting in the fusion protein PAX3-FOXO1. Despite aggressive therapy, the 5-year survival rate for patients with high risk or recurrent Fusion Positive RMS (FP-RMS) is low (~30% and ~17%, respectively). Therefore, new therapies targeting the PAX3-FOXO1 oncogenic driver are urgently needed.
Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients
Summary:
NCI seeks commercial partners to co-develop and/or license a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL).
Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)
Summary:
NCI seeks commercial partners to co-develop and/or license a novel method to identify neoantigen reactive T cells and TCRs.
Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo
Summary:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of multidimensional MRI-based methods.
Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer
Summary:
The National Cancer Institute (NCI) seeks licensees for a family of novel furoquinolinedione derivatives that inhibit tyrosyl-DNA phosphodiesterase 2 (TDP2) as cancer therapeutics.